{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-038478","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.067604+00:00","generated_at":"2026-05-16T12:25:31.785804+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Moleculin Biotech Reduces Warrant Exercise Price to $3.90, Boosts Equity Above $10M to Address Nasdaq Delisting","bullets":["Entered warrant amendment agreements on Dec 21, 2025 reducing exercise price of Series E, F, G warrants to $3.90 per share.","Amended Series E and F warrants to delete certain anti-dilution provisions and modify Black Scholes Value definition.","Received Nasdaq delisting notice on Nov 20, 2025 for non-compliance with $2.5M equity rule; appealed and hearing set for Jan 20, 2026.","Raised $6.8M from warrant exercise on Dec 9, 2025 and $1.1M from ATM facility; stockholders' equity now exceeds $10.0M.","Panel hearing for Nasdaq appeal scheduled for January 20, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-038478","json":"https://secwatch.observer/filing/0001437749-25-038478.json","markdown":"https://secwatch.observer/filing/0001437749-25-038478.md","text":"https://secwatch.observer/filing/0001437749-25-038478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925038478/0001437749-25-038478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925038478/mbrx20251221_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T12:25:31.785804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7c7cb47f3976b8f05d91aa488c3b1d17dd6da4f","claim":"Moleculin Biotech, Inc. amended Warrant Amendment with holders of the Company’s Series E warrants, Series F warrants, and Series G warrants valued at $3.90 per share (effective 2025-12-21).","evidence_excerpt":"On December 21, 2025, Moleculin Biotech, Inc. (the “Company”) entered into separate warrant amendment agreements (collectively, the “Warrant Amendment”) with the holders of the Company’s Series E warrants (the “Series E warrants”), Series F warrants (the “Series F warrants”), and Series G warrants (the “Series G warrants,” and collectively with the Series E warrants and Series F warrants, the “Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925038478/0001437749-25-038478-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"holders of the Company’s Series E warrants, Series F warrants, and Series G warrants"},{"label":"Value","value":"$3.90 per share"},{"label":"Effective","value":"2025-12-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}